Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients

Lung Cancer

Volumn 81, Issue 3, 2013, Pages 455-461

  Hsiao, Shih Hsin ^a   Lin, Horng Chyuan ^b   Chou, Yu Ting ^c   Lin, Sey En ^a   Kuo, Chia Chun ^a   Yu, Ming Chih ^d   Chung, Chi Li ^a,e  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Brain metastases; Epidermal growth factor receptor mutations; Lung adenocarcinoma; Radiotherapy; Survival after brain metastases; Treatment response

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TREATMENT RESPONSE;

BRAIN METASTASES; EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS; LUNG ADENOCARCINOMA; RADIOTHERAPY; SURVIVAL AFTER BRAIN METASTASES; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84881667804     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.06.004     Document Type: Article

References (28)

1. Sorensen J.B., Hansen H.H., Hansen M., Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988, 6:1474-1480.
2. Bajard A., Westeel V., Dubiez A., Jacoulet P., Pernet D., Dalphin J.C., et al. Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer 2004, 45:317-323.
3. Monaco E.A., Faraji A.H., Berkowitz O., Parry P.V., Hadelsberg U., Kano H., et al. Leukoencephalopathy after whole-brain radiation therapy plus radiosurgery versus radiosurgery alone for metastatic lung cancer. Cancer 2013, 119:226-232.
4. Crossen J.R., Garwood D., Glatstein E., Neuwelt E.A. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994, 12:627-642.
5. Hubbs J.L., Boyd J.A., Hollis D., Chino J.P., Saynak M., Kelsey C.R. Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer 2010, 116:5038-5046.
6. Bhangoo S.S., Linskey M.E., Kalkanis S.N. Evidence-based guidelines for the management of brain metastases. Neurosurg Clin N Am 2011, 22:97-104. viii.
7. Minniti G., Salvati M., Muni R., Lanzetta G., Osti M.F., Clarke E., et al. Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer. Anticancer Res 2010, 30:3055-3061.
8. Davey P. Brain metastases: treatment options to improve outcomes. CNS Drugs 2002, 16:325-338.
9. Gondi V., Mehta M.P. Novel insights into the management of brain metastases. Curr Opin Neurol 2010, 23:556-562.
10. Franceschi E., Brandes A.A. Brain metastases from non-small-cell lung cancer: is there room for improvement?. Expert Rev Anticancer Ther 2012, 12:421-423.
11. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
12. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
13. Gow C.H., Chien C.R., Chang Y.L., Chiu Y.H., Kuo S.H., Shih J.Y., et al. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. Clin Cancer Res 2008, 14:162-168.
14. Eichler A.F., Kahle K.T., Wang D.L., Joshi V.A., Willers H., Engelman J.A., et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol 2010, 12:1193-1199.
15. Grommes C., Oxnard G.R., Kris M.G., Miller V.A., Pao W., Holodny A.I., et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol 2011, 13:1364-1369.
16. Jamal-Hanjani M., Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res 2012, 18:938-944.
17. Nishino M., Jackman D.M., Hatabu H., Yeap B.Y., Cioffredi L.A., Yap J.T., et al. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol 2010, 195:W221-W228.
18. Dittmann K., Mayer C., Fehrenbacher B., Schaller M., Raju U., Milas L., et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 2005, 280:31182-31189.
19. Das A.K., Sato M., Story M.D., Peyton M., Graves R., Redpath S., et al. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation. Cancer Res 2006, 66:9601-9608.
20. Das A.K., Chen B.P., Story M.D., Sato M., Minna J.D., Chen D.J., et al. Somatic mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR) abrogate EGFR-mediated radioprotection in non-small cell lung carcinoma. Cancer Res 2007, 67:5267-5274.
21. Liccardi G., Hartley J.A., Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res 2011, 71:1103-1114.
22. Shimato S., Mitsudomi T., Kosaka T., Yatabe Y., Wakabayashi T., Mizuno M., et al. EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol 2006, 8:137-144.
23. Wu C., Li Y.L., Wang Z.M., Li Z., Zhang T.X., Wei Z. Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. Lung Cancer 2007, 57:359-364.
24. Porta R., Sanchez-Torres J.M., Paz-Ares L., Massuti B., Reguart N., Mayo C., et al. Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation. Eur Respir J 2011, 37:624-631.
25. Kim J.E., Lee D.H., Choi Y., Yoon D.H., Kim S.W., Suh C., et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009, 65:351-354.
26. Yatabe Y., Matsuo K., Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 2011, 29:2972-2977.
27. Welsh J.W., Komaki R., Amini A., Munsell M.F., Unger W., Allen P.K., et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013, 31:895-902.
28. Henson J.W., Ulmer S., Harris G.J. Brain tumor imaging in clinical trials. Am J Neuroradiol 2008, 29:419-424.